Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice

Journal of International Medical Research

Volumn 38, Issue 4, 2010, Pages 1413-1427

  Gao, J ^a   Jia, W D ^a   Li, J S ^a   Wang, W ^a   Xu, G L ^a   Ma, J L ^a   Ge, Y S ^a   Yu, J H ^a   Ren, W H ^a   Liu, W B ^a   Zhang, C H ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; COX 2 inhibitors; Fluvastatin; Hepatocellular carcinoma; Nude mice; Signalling pathway; Statins

Indexed keywords

CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUINDOSTATIN; PROTEIN KINASE B; PROTEIN MCL 1; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION; WESTERN BLOTTING;

EID: 77957730454     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800423     Document Type: Article

References (75)

1. Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Bruix J, Barrera JM, Calvet X, et al: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepato-cellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006.
3. Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepato-cellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440.
4. Hwang S, Lee SG, Joh JW, et al: Liver transplantation for adult patients with hepato-cellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005; 11: 1265-1272.
5. Sergio A, Cristofori C, Cardin R, et al: Transcatheter arterial chemoembolization (TACE) in hepato-cellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921.
6. Curley SA, Izzo F, Ellis LM, et al: Radiofrequency ablation of hepato-cellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
7. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepato-cellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
8. Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286.
9. ∆716 mouse intestinal polyps. Cancer Res 2002; 62: 506-511.
10. Sumitani K, Kamijo R, Toyoshima T, et al: Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 2001; 30: 41-47.
11. Sheng H, Shao J, Morrow JD, et al: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362-366.
12. Shiota G, Okubo M, Noumi T, et al: Cyclooxygenase-2 expression in hepato-cellular carcinoma. Hepato-gastroenterology 1999; 46: 407-412.
13. Tucker ON, Dannenberg AJ, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-990.
14. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
15. Gupta S, Srivastava M, Ahmad N, et al: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-78.
16. Zhang H, Sun XF: Over-expression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97: 1037-1041.
17. Qin J, Yuan J, Li L, et al: In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother 2009; 63: 241-248.
18. Xu XF, Xie CG, Wang XP, et al: Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008; 215: 149-157.
19. Cui W, Yu CH, Hu KQ: In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepato-cellular carcinoma cells. Clin Cancer Res 2005; 11: 8213-8221.
20. Xin B, Yokoyama Y, Shigeto T, et al: Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor γ ligand, on the growth of human ovarian cancers. Cancer 2007; 110: 791-800.
21. Caldwell B, Aldington S, Weatherall M, et al: Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132-140.
22. Plosker GL, Wagstaff AJ: Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996; 51: 433-459.
23. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
24. Caruso MG, Notarnicola M, Cavallini A, et al: 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol 2002; 33: 504-508.
25. Kawata S, Takaishi K, Nagase T, et al: Increase in active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepato-cellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990; 50: 3270-3273.
26. Sola S, Mir MQ, Rajagopalan S, et al: Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 2005; 11: 607-612.
27. Sutter AP, Maaser K, Höpfner M, et al: Cell cycle arrest and apoptosis induction in hepato-cellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic anti-proliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43: 808-816.
28. Zheng X, Cui XX, Avila GE, et al: Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007; 13: 5480-5487.
29. Swamy MV, Patlolla JM, Steele VE, et al: Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006; 66: 7370-7377.
30. Campbell MJ, Esserman LJ, Zhou Y, et al: Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707-8714.
31. Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharm 1989; 24: 148-154.
32. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
33. Huynh H, Soo KC, Chow PK, et al: Xenografts of human hepato-cellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006; 12: 4306-4314.
34. Han C, Leng J, Demetris AJ, et al: Cyclo-oxygenase-2 promotes human cholangio-carcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004; 64: 1369-1376.
35. Narayana BA, Condon MS, Bosland MC, et al: Suppression of N-methyl-N-nitrosourea/ testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003; 9: 3503-3513.
36. Hoque A, Chen H, Xu XC: Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008; 17: 88-94.
37. Saito A, Saito N, Mol W, et al: Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res 2008; 18: 85-94.
38. Dai Y, Khanna P, Chen S, et al: Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 2007; 109: 4415-4423.
39. Ogunwobi OO, Beales IL: Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103: 825-837.
40. Kern MA, Haugg AM, Koch AF, et al: Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepato-cellular carcinoma. Cancer Res 2006; 66: 7059-7066.
41. Jia WD, Xu GL, Xu RN, et al: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepato-cellular carcinoma xenografts. J Cancer Res Clin Oncol 2003; 129: 327-334.
42. Xu Y, Wen Z, Xu Z: Chitosan nanoparticles inhibit the growth of human hepato-cellular carcinoma xenografts through an antiangiogenic mechanism. Anticancer Res 2009; 29: 5103-5109.
43. Urbich C, Dernbach E, Zeiher AM, et al: Doubleedged role of statins in angiogenesis signaling. Circ Res 2002; 90: 737-744.
44. Khaidakov M, Wang W, Khan JA, et al: Statins and angiogenesis: is it about connections? Biochem Biophys Res Commun 2009; 387: 543-547.
45. Kim W, Yoon JH, Kim JR, et al: Synergistic antitumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepato-cellular carcinoma. Cancer Chemother Pharmacol 2009; 64: 497-507.
46. Cully M, You H, Levine AJ, et al: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192.
47. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
48. Tang JM, He QY, Guo RX, et al: Phosphorylated Akt Over-expression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-191.
49. Yamamoto S, Tomita Y, Hoshida Y, et al: Prognostic significance of activated Akt expression in pancreatic ductal adeno-carcinoma. Clin Cancer Res 2004; 10: 2846-2850.
50. Ayala G, Thompson T, Yang G, et al: High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004; 10: 6572-6578.
51. Nakanishi K, Sakamoto M, Yamasaki S, et al: Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepato-cellular carcinoma. Cancer 2005; 103: 307-312.
52. Schmitz KJ, Wohlschlaeger J, Lang H, et al: Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepato-cellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.
53. Kulp SK, Yang YT, Hung CC: 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64: 1444-1451.
54. Dimmeler S, Aicher A, Vasa M, et al: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397.
55. Roudier E, Mistafa O, Stenius U: Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 2006; 5: 2706-2715.
56. Mistafa O, Stenius U: Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 2009; 78: 1115-1126.
57. Zhang Z, Lai GH, Sirica AE: Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39: 1028-1037.
58. Xiao H, Zhang Q, Lin Y, et al: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008; 122: 2115-2124.
59. Lin YC, Lin JH, Chou CW, et al: Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 2008; 68: 2375-2383.
60. Sieghart W, Losert D, Strommer S, et al: Mcl-1 Over-expression in hepato-cellular carcinoma: a potential target for antisense therapy. J Hepatol 2006; 44: 151-157.
61. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepato-cellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858.
62. Fleischer B, Schulze-Bergkamen H, Schuchmann M, et al: Mcl-1 is an antiapoptotic factor for human hepato-cellular carcinoma. Int J Oncol 2006; 28: 25-32.
63. van de Donk NW, Kamphuis MM, van Kessel B, et al: Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003; 102: 3354-3362.
64. Lu G, Xiao H, You H, et al: Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res 2008; 14: 4981-4988.
65. Shin S, Sung BJ, Cho YS, et al: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and caspase-7. Biochemistry 2001; 40: 1117-1123.
66. Zhang X, Dong N, Yin L, et al: Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol 2005; 77: 374-381.
67. Lo Muzio L, Campisi G, Giovannelli L, et al: HPV DNA and survivin expression in epithelial oral carcinogenesis: a relationship? Oral Oncol 2004; 40: 736-741.
68. Reddy VG, Khanna N, Singh N: Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun 2001; 282: 409-415.
69. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
70. Lu B, Mu Y, Cao C, et al: Survivin as a therapeutic target for radiation sensitization in lung. Cancer Res 2004; 64: 2840-2845.
71. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, et al: Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Biophys Res Commun 2007; 357: 1166-1171.
72. Herrero-Martin G, López-Rivas A: Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins. FEBS Lett 2008; 582: 2589-2594.
73. Grösch S, Maier TJ, Schiffmann S, et al: Cyclooxygenase-2 independent anticarcino-genic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747.
74. Maier TJ, Schilling K, Schmidt R, et al: Cyclooxygenase-2 (COX-2)-dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67: 1469-1478.
75. Yang Z, Xiao H, Jin H, et al: Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer 2010; 126: 852-863.